U.S. FDA to Review Merck & Co., Inc. (JOBS), Schering-Plough Corporation (JOBS) Data on Vytorin Cancer Risk

August 22, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

WASHINGTON, Aug 21 (Reuters) - U.S. Food and Drug Administration officials plan to review recently publicized data that showed a higher rate of cancer in patients taking Merck & Co Inc and Schering-Plough Corp's cholesterol drug Vytorin.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Postmarket research

Merck & Co. Food and Drug Administration (FDA)